These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 3129447)

  • 1. Hormonal effects of single gonadotropin-releasing hormone antagonist doses in men.
    Jockenhövel F; Bhasin S; Steiner BS; Rivier JE; Vale WW; Swerdloff RS
    J Clin Endocrinol Metab; 1988 May; 66(5):1065-70. PubMed ID: 3129447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate.
    Tom L; Bhasin S; Salameh W; Steiner B; Peterson M; Sokol RZ; Rivier J; Vale W; Swerdloff RS
    J Clin Endocrinol Metab; 1992 Aug; 75(2):476-83. PubMed ID: 1639948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concordant suppression of serum immunoreactive luteinizing hormone (LH), follicle-stimulating hormone, alpha subunit, bioactive LH, and testosterone in postmenopausal women by a potent gonadotropin releasing hormone antagonist (detirelix).
    Andreyko JL; Monroe SE; Marshall LA; Fluker MR; Nerenberg CA; Jaffe RB
    J Clin Endocrinol Metab; 1992 Feb; 74(2):399-405. PubMed ID: 1370507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Marked suppression of gonadotropins and testosterone by an antagonist analog of gonadotropin-releasing hormone in men.
    Salameh W; Bhasin S; Steiner B; McAdams LA; Peterson M; Swerdloff R
    Fertil Steril; 1991 Jan; 55(1):156-64. PubMed ID: 1898888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective suppression of luteinizing hormone and testosterone by single doses of the new gonadotropin-releasing hormone antagonist cetrorelix (SB-75) in normal men.
    Behre HM; Klein B; Steinmeyer E; McGregor GP; Voigt K; Nieschlag E
    J Clin Endocrinol Metab; 1992 Aug; 75(2):393-8. PubMed ID: 1639941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mode of suppression of pituitary and gonadal function after acute or prolonged administration of a luteinizing hormone-releasing hormone antagonist in normal men.
    Pavlou SN; Wakefield G; Schlechter NL; Lindner J; Souza KH; Kamilaris TC; Konidaris S; Rivier JE; Vale WW; Toglia M
    J Clin Endocrinol Metab; 1989 Feb; 68(2):446-54. PubMed ID: 2537334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effects of two different delivery systems on gonadotropin-releasing hormone (GnRH) antagonist-induced suppression of gonadotropins and testosterone in man.
    Salameh W; Bhasin S; Steiner BS; McAdams LA; Peterson M; Rivier JE; Vale WW; Swerdloff RS
    J Androl; 1994; 15(1):22-8. PubMed ID: 8188535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of the suppressive effects of testosterone and a potent new gonadotropin-releasing hormone antagonist on gonadotropin and inhibin levels in normal men.
    Bagatell CJ; McLachlan RI; de Kretser DM; Burger HG; Vale WW; Rivier JE; Bremner WJ
    J Clin Endocrinol Metab; 1989 Jul; 69(1):43-8. PubMed ID: 2499592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential regulation of luteinizing hormone, follicle-stimulating hormone, and free alpha-subunit secretion from the gonadotrope by gonadotropin-releasing hormone (GnRH): evidence from the use of two GnRH antagonists.
    Hall JE; Whitcomb RW; Rivier JE; Vale WW; Crowley WF
    J Clin Endocrinol Metab; 1990 Feb; 70(2):328-35. PubMed ID: 2105329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistence of concordant luteinizing hormone (LH), testosterone, and alpha-subunit pulses after LH-releasing hormone antagonist administration in normal men.
    Pavlou SN; Veldhuis JD; Lindner J; Souza KH; Urban RJ; Rivier JE; Vale WW; Stallard DJ
    J Clin Endocrinol Metab; 1990 May; 70(5):1472-8. PubMed ID: 2110578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single subcutaneous doses of a luteinizing hormone-releasing hormone antagonist suppress serum gonadotropin and testosterone levels in normal men.
    Pavlou SN; Debold CR; Island DP; Wakefield G; Rivier J; Vale W; Rabin D
    J Clin Endocrinol Metab; 1986 Aug; 63(2):303-8. PubMed ID: 3088019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the antigonadotropic activity of three GnRH antagonists (Nal-Glu, Antide and Cetrorelix) in a non-human primate model (Macaca fascicularis).
    Weinbauer GF; Nieschlag E
    Andrologia; 1993; 25(3):141-7. PubMed ID: 8517553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of pituitary-gonadal function by a potent new luteinizing hormone-releasing hormone antagonist in normal men.
    Pavlou SN; Wakefield GB; Island DP; Hoffman PG; LePage ME; Chan RL; Nerenberg CA; Kovacs WJ
    J Clin Endocrinol Metab; 1987 May; 64(5):931-6. PubMed ID: 3104388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormonal responses to the new potent GnRH antagonist Cetrorelix.
    Klingmüller D; Schepke M; Enzweiler C; Bidlingmaier F
    Acta Endocrinol (Copenh); 1993 Jan; 128(1):15-8. PubMed ID: 8447189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of plasma gonadotropins and testosterone in adult male monkeys (Macaca fascicularis) by a potent inhibitory analog of gonadotropin-releasing hormone.
    Adams LA; Bremner WJ; Nestor JJ; Vickery BH; Steiner RA
    J Clin Endocrinol Metab; 1986 Jan; 62(1):58-63. PubMed ID: 3079603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The importance of luteinizing hormone in the control of inhibin and progesterone secretion by the human corpus luteum.
    McLachlan RI; Cohen NL; Vale WW; Rivier JE; Burger HG; Bremner WJ; Soules MR
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1078-85. PubMed ID: 2498381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of administration of a gonadotropin-releasing hormone (GnRH) antagonist (Nal-Glu) during the periovulatory period: the luteinizing hormone surge requires secretion of GnRH.
    Dubourdieu S; Charbonnel B; D'Acremont MF; Carreau S; Spitz IM; Bouchard P
    J Clin Endocrinol Metab; 1994 Feb; 78(2):343-7. PubMed ID: 8106622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens.
    Bagatell CJ; Matsumoto AM; Christensen RB; Rivier JE; Bremner WJ
    J Clin Endocrinol Metab; 1993 Aug; 77(2):427-32. PubMed ID: 8345047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High loading and low maintenance doses of a gonadotropin-releasing hormone antagonist effectively suppress serum luteinizing hormone, follicle-stimulating hormone, and testosterone in normal men.
    Behre HM; Kliesch S; Pühse G; Reissmann T; Nieschlag E
    J Clin Endocrinol Metab; 1997 May; 82(5):1403-8. PubMed ID: 9141524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormonal responses to a potent gonadotropin hormone-releasing hormone antagonist in normal elderly men.
    Tenover JS; Dahl KD; Vale WW; Rivier JE; Bremner WJ
    J Clin Endocrinol Metab; 1990 Oct; 71(4):881-8. PubMed ID: 2205625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.